PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30497065-0 2018 Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Nelfinavir 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 31262902-11 2019 In particular, the sensitizing effect of co-treatment with nelfinavir on antimitotic drug-resistant cancer cells was found to be strong and independent of P-gp-inhibitory activity. Nelfinavir 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 31262902-12 2019 As P-gp inhibition can be toxic to normal cells, selecting nelfinavir may be safer for normal cells in patients with drug-resistant cancer. Nelfinavir 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 3-7 33483427-8 2021 Physiological relevance of nelfinavir-dependent modulation of PXR activity was investigated in respectively treated primary human hepatocytes, which showed differential induction of PXR target genes and antagonism of rifampin-induced ABCB1 and CYP3A4 gene expression. Nelfinavir 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 234-239 28676669-0 2018 Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Nelfinavir 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 28676669-0 2018 Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Nelfinavir 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 28676669-8 2018 In search for potential drugs targeting ABCB1 in clinical trials, we identified the HIV protease inhibitors nelfinavir (NFV) and lopinavir (LPV) as potent functional modulators of ABCB1-mediated drug export, most likely via modulation of mitochondria permeability transition pore. Nelfinavir 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 28676669-8 2018 In search for potential drugs targeting ABCB1 in clinical trials, we identified the HIV protease inhibitors nelfinavir (NFV) and lopinavir (LPV) as potent functional modulators of ABCB1-mediated drug export, most likely via modulation of mitochondria permeability transition pore. Nelfinavir 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 180-185 23082557-2 2012 A previous study showed that ABCB-1 C3435T polymorphism affects plasma efavirenz and nelfinavir concentrations and rate of CD4+ T cell recovery after starting antiretroviral treatment (ART). Nelfinavir 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 29-35 24364805-2 2014 However, such interactions at clinically relevant CsA blood concentrations may be greater for substrates where P-gp plays an even larger role (fractional contribution of P-gp, ft > 0.97) in preventing the CNS entry of the drug (e.g., nelfinavir). Nelfinavir 237-247 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 24364805-6 2014 Then, using these data, as well as in vitro data in LLCPK1 cells expressing the human P-gp, we predicted that CsA (at clinically relevant blood concentration of 1.5 muM) will increase the distribution of nelfinavir into the human brain by 236%. Nelfinavir 204-214 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 22017299-6 2012 The stimulation of the GSH export from viable astrocytes by indinavir or nelfinavir was completely prevented by the application of MK571, an inhibitor of the multidrug resistance protein 1. Nelfinavir 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 158-188 22017299-7 2012 These data demonstrate that indinavir and nelfinavir stimulate multidrug resistance protein 1-mediated GSH export from viable astrocytes and suggest that treatment of patients with such inhibitors may affect the GSH homeostasis in brain. Nelfinavir 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 63-93 18393290-5 2008 In cell accumulation studies, Pluronic P85 restored the accumulation of nelfinavir in MDCKII-MDR1 cells while Pluronic F127 and F88 had no effect. Nelfinavir 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 19478134-3 2009 Nelfinavir is cleared from the body predominantly by CYP3A metabolism and P-glycoprotein (P-gp) efflux. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 19478134-3 2009 Nelfinavir is cleared from the body predominantly by CYP3A metabolism and P-glycoprotein (P-gp) efflux. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 16267764-2 2005 Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 17591677-7 2007 Our data indicate that nelfinavir has poor penetration into the macaque"s brain and CSF, and P-gp inhibition at the BBB by zosuquidar enhanced the distribution of nelfinavir into the brain by 146-fold. Nelfinavir 163-173 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 17047492-10 2006 Among 155 participants who received efavirenz without nelfinavir, virologic failure was associated with a two-locus interaction between ABCB1 2677G>T and CYP2B6 516G>T (65% accuracy, P<0.001). Nelfinavir 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 136-141 17591677-0 2007 Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Nelfinavir 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 17591677-9 2007 In conclusion, P-gp inhibition at the nonhuman primate BBB significantly enhanced the distribution of nelfinavir into the brain, and this effect was not observed in the CSF. Nelfinavir 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 16165208-9 2006 This MDR1 overexpression was observed in a similar extent in placentas from pregnant women treated with Zidovudine alone or in combination with Nelfinavir and/or Lamivudine. Nelfinavir 144-154 ATP binding cassette subfamily B member 1 Homo sapiens 5-9 16267764-2 2005 Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 15040543-0 2004 Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Nelfinavir 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 15750390-0 2005 An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. Nelfinavir 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 3-7 15750390-2 2005 This research examined the impact of single nucleotide polymorphisms (SNP) of MDR1 and CYP genes on nelfinavir and efavirenz pharmacokinetics and the response to highly active antiretroviral therapy (HAART) in HIV-1 infected children. Nelfinavir 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 15750390-10 2005 CONCLUSIONS: HIV-1 infected children with the MDR1-3435-C/T genotype had more rapid virologic responses to HAART at week 8 with higher plasma nelfinavir concentrations compared to those with the C/C genotype. Nelfinavir 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 15750390-11 2005 These findings suggest that P-gp may play an important role in the pharmacokinetics and virologic response to HAART containing nelfinavir. Nelfinavir 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 15651752-0 2004 Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Nelfinavir 106-116 ATP binding cassette subfamily B member 1 Homo sapiens 52-74 15040543-1 2004 OBJECTIVE: To compare plasma and intracellular nelfinavir pharmacokinetics, and determine their relationship to P-glycoprotein (P-gp) expression and function in lymphocytes of HIV-infected patients. Nelfinavir 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 15040543-10 2004 In patients chronically treated with nelfinavir mean P-gp expression was 8.85 +/- 1.3 MFI, there was no correlation between P-gp expression and either intracellular AUC(0-12) (r=-0.35; P=0.29) or intracellular C0 values. Nelfinavir 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 15040543-11 2004 There was a correlation between intracellular nelfinavir concentrations and P-gp function at baseline (r=0.59; P<0.05). Nelfinavir 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 15040543-15 2004 CONCLUSIONS: Nelfinavir undergoes significant intracellular accumulation within the PBMCs of HIV-infected patients, which may be in part related to its moderate ability to inhibit P-gp-mediated drug efflux. Nelfinavir 13-23 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 15040543-17 2004 Intracellular accumulation of nelfinavir correlated with P-gp function but not P-gp expression, suggesting pump activity is substrate concentration-dependant. Nelfinavir 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 12902797-6 2003 Significant increases in median P-gp expression were observed following incubation with 10 microM nelfinavir (10.2 versus 6.7% P-gp-positive cells) and efavirenz (10.0 versus 6.7% P-gp-positive cells). Nelfinavir 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 12917239-7 2003 Nelfinavir, however, increased P-gp expression. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 12917239-9 2003 CONCLUSION: This study suggests that, of the PIs, only nelfinavir increases P-gp expression in vitro, and in vivo the PI class of antiretrovirals do not increase P-gp expression on lymphocytes. Nelfinavir 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 12902797-6 2003 Significant increases in median P-gp expression were observed following incubation with 10 microM nelfinavir (10.2 versus 6.7% P-gp-positive cells) and efavirenz (10.0 versus 6.7% P-gp-positive cells). Nelfinavir 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 12902797-6 2003 Significant increases in median P-gp expression were observed following incubation with 10 microM nelfinavir (10.2 versus 6.7% P-gp-positive cells) and efavirenz (10.0 versus 6.7% P-gp-positive cells). Nelfinavir 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 12902797-9 2003 However, nelfinavir, ritonavir, and lopinavir caused marked toxicity, indicating that at higher concentrations, the increase in P-gp may be at least partially related to a stress response. Nelfinavir 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 11468419-4 2001 We found that HIV-PIs (i.e., ritonavir, saquinavir, nelfinavir and indinavir) interfere with P-gp function in normal PBLs as demonstrated by the reduced efflux of rhodamine 123 (Rh123). Nelfinavir 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 11302944-9 2001 Nelfinavir treatment increased expression of intestinal Pgp and hepatic CYP3A levels by 83 and 85%, respectively, but not hepatic Pgp or intestinal CYP3A. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 56-59 10509562-14 1999 CONCLUSIONS: We have demonstrated that saquinavir is a substrate for P-gp and that ritonavir, nelfinavir and indinavir modulate P-gp function in both human lymphocytes and Caco-2 cells. Nelfinavir 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 11185676-9 2000 Inhibition of p-glycoprotein by nelfinavir may be responsible for this significant interaction. Nelfinavir 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 10820137-3 2000 Intravenous administration of the novel and potent P-glycoprotein inhibitor LY-335979 to mice (1-50 mg/kg) increased brain and testes concentration of [(14)C]nelfinavir, up to 37- and 4-fold, respectively, in a dose-dependent fashion. Nelfinavir 158-168 ATP binding cassette subfamily B member 1 Homo sapiens 51-65 10509562-1 1999 OBJECTIVES: To determine the effect of the protease inhibitors ritonavir, nelfinavir and indinavir on the P-glycoprotein (P-gp)-mediated transport of saquinavir in Caco-2 cell monolayers. Nelfinavir 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 106-120 10509562-1 1999 OBJECTIVES: To determine the effect of the protease inhibitors ritonavir, nelfinavir and indinavir on the P-glycoprotein (P-gp)-mediated transport of saquinavir in Caco-2 cell monolayers. Nelfinavir 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 10509562-2 1999 To study the modulation of P-gp function in human lymphocytes by saquinavir, ritonavir, nelfinavir and indinavir. Nelfinavir 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 9803961-6 1998 Saquinavir, ritonavir and nelfinavir significantly inhibited the efflux of [3H]paclitaxel and [3H]vinblastine in P-gp-positive cells, resulting in an increase in intracellular accumulation of these drugs. Nelfinavir 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 9803961-9 1998 These data suggest that saquinavir, ritonavir, and nelfinavir are inhibitors and possibly substrates of P-gp. Nelfinavir 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 34158378-6 2021 Nelfinavir affected the fluidity and composition of lipid-rich membranes, disrupted mitochondrial respiration, blocked vesicular transport, and affected the function of membrane-embedded drug efflux transporter ABCB1, triggering the integrated stress response. Nelfinavir 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 211-216 9835508-1 1998 The human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs)-saquinavir, ritonavir, nelfinavir, and indinavir-interact with the ABC-type multidrug transporter proteins MDR1 and MRP1 in CEM T-lymphocytic cell lines. Nelfinavir 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 181-185